
Basilea Pharmaceutica AG (OTCMKTS:BPMUF – Free Report) – Analysts at HC Wainwright issued their FY2027 EPS estimates for shares of Basilea Pharmaceutica in a research report issued on Friday, November 13th. HC Wainwright analyst R. Selvaraju expects that the company will post earnings of $7.60 per share for the year.
Basilea Pharmaceutica Stock Performance
BPMUF stock opened at $84.00 on Monday. The company has a fifty day moving average price of $77.28 and a 200 day moving average price of $70.05. Basilea Pharmaceutica has a 12 month low of $59.29 and a 12 month high of $84.00. The company has a current ratio of 6.60, a quick ratio of 5.97 and a debt-to-equity ratio of 0.44.
About Basilea Pharmaceutica
Basilea Pharmaceutica is a Swiss biopharmaceutical company founded in 2000 and headquartered in Basel. It focuses on developing and commercializing medicines for serious bacterial and fungal infections. The company’s products include Cresemba (isavuconazole), an antifungal medicine used to treat invasive aspergillosis and mucormycosis, and Zevtera (ceftobiprole), an antibiotic used for certain serious bacterial infections. Basilea makes its medicines available in multiple countries through a combination of its own commercial activities and partnerships.
Featured Articles
- Five stocks we like better than Basilea Pharmaceutica
- Ondas Is Building a Defense Growth Engine, But Can It Deliver on Its Backlog?
- Orbiting Growth: Federal Contracts Boost Viasat’s Outlook
- Modine Manufacturing Scales Up to Solve the AI Heat Problem
- Nebius Revenue Is Surging, But Its Spending Is Raising Bigger Questions
Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.
